Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.
Abstract: Pharmaceutical compositions and methods for inducing conscious sedation using such compositions are described, the compositions including a benzodiazepine-based compound, a NMDA antagonist, and optionally a ?-blocker, antiemetic, an NSAID, and/or an antihistamine medication. Methods for fabricating the compositions and using them for anesthesiological applications are also described.
Type:
Grant
Filed:
February 23, 2018
Date of Patent:
January 15, 2019
Assignee:
Imprimis Pharmaceuticals, Inc.
Inventors:
John Berdahl, William F. Wiley, Dennis Elias Saadeh
Abstract: Pharmaceutical compositions and methods for inducing conscious sedation using such compositions are described, the compositions including a benzodiazepine-based compound, a NMDA antagonist, and optionally a ?-blocker, antiemetic, an NSAID, and/or an antihistamine medication. Methods for fabricating the compositions and using them for anesthesiological applications are also described.
Type:
Grant
Filed:
February 23, 2018
Date of Patent:
January 1, 2019
Assignee:
Imprimis Pharmaceuticals, Inc.
Inventors:
John Berdahl, William F. Wiley, Dennis Elias Saadeh
Abstract: Pharmaceutical compositions and methods are described, the compositions comprising a benzodiazepine-based compound, a NMDA antagonist, a ?-blocker and antiemetic. Methods for fabricating the compositions and using them for anesthesiological applications are also described.
Type:
Grant
Filed:
June 16, 2016
Date of Patent:
March 20, 2018
Assignee:
IMPRIMIS PHARMACEUTICALS, INC.
Inventors:
John Berdahl, William F. Wiley, Dennis Elias Saadeh
Abstract: Medical articles are described, comprising a lens and a pharmaceutical composition incorporated into the lens, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone) and at least one pharmaceutically acceptable excipient. Methods for fabricating the medical articles and using them are also described.
Type:
Grant
Filed:
March 10, 2016
Date of Patent:
November 14, 2017
Assignee:
Imprimis Pharmaceuticals, Inc.
Inventors:
Gary Seelhorst, Thomas Harvey, Mark L. Baum
Abstract: The present invention relates to pharmaceutical formulations comprising tranexamic acid, kits thereof, and methods for treating bleeding by local administration.
Type:
Grant
Filed:
July 8, 2014
Date of Patent:
April 5, 2016
Assignee:
Imprimis Pharmaceuticals, Inc.
Inventors:
Matthew James Buderer, Jeffrey Joel Abrams
Abstract: Medical article are described, comprising a lens and a pharmaceutical composition incorporated into the lens, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone) and at least one pharmaceutically acceptable excipient. Methods for fabricating the medical articles and using them are also described.
Type:
Application
Filed:
August 12, 2014
Publication date:
February 18, 2016
Applicant:
IMPRIMIS PHARMACEUTICALS, INC.
Inventors:
Gary Seelhorst, Thomas Harvey, Mark L. Baum
Abstract: Pharmaceutical compositions are described, the compositions comprising a therapeutically effective quantity of an active component and a quantity of a sterile gel. Methods for fabricating the compositions and using them for ophthalmic or burn-treating applications are also described.
Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as triamcinolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described.
Type:
Application
Filed:
February 23, 2015
Publication date:
June 18, 2015
Applicant:
IMPRIMIS PHARMACEUTICALS, INC.
Inventors:
Richard Dilzer, Forest J. Flodin, Joseph S. Bitterman, Mark L. Baum
Abstract: Pharmaceutical compositions for intraocular administration are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as triamcinolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular administration are also described as well as pharmaceutical kits designed for administering the compositions.
Type:
Application
Filed:
January 14, 2015
Publication date:
May 14, 2015
Applicant:
IMPRIMIS PHARMACEUTICALS, INC.
Inventors:
Forest J. Flodin, John P. Saharek, Mark L. Baum, Richard Dilzer
Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described.
Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as triamcinolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described.
Type:
Application
Filed:
March 27, 2014
Publication date:
January 22, 2015
Applicant:
IMPRIMIS PHARMACEUTICALS, INC.
Inventors:
Jeffrey T. LIEGNER, John Scott Karolchyk, Bernard Covalesky, Richard Dilzer, Kallan Peters
Abstract: A cellulite-reducing topical composition comprising a lecithin organogel, an ethylene oxide-propylene oxide-ethylene oxide triblock copolymer, caffeine, a retinoid, and optionally at least one vitamin, vitamin derivative or vitamin precursor.
Type:
Application
Filed:
June 13, 2011
Publication date:
August 15, 2013
Applicant:
IMPRIMIS PHARMACEUTICALS, INC.
Inventors:
Joseph Grasela, Joachim Schupp, Sergio Nacht